Newsletters

[Experimental & Molecular Medicine] Single-cell RNA-sequencing and multiplex immunohistochemistry analyses demonstrated upregulated expression of inducible T cell co-stimulator ligand (ICOSLG) and RUNX1 in psoriatic keratinocytes.

[Biofabrication] Investigators developed and assessed a physiologically relevant scaffold-free 3D melanoma model that mimics the morphological and functional features of the melanoma lesion.

[Vanda Pharmaceuticals Inc.] Vanda Pharmaceuticals Inc. announced that Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 monoclonal antibody, for the treatment of generalized pustular psoriasis.

[Signal Transduction and Targeted Therapy] Researchers developed a synthetic T cell receptor and antigen receptor-T (STAR-T) cell therapy targeting leukocyte immunoglobulin-like receptor B4 (LILRB4), an immunosuppressive receptor highly expressed on monocytic acute myeloid leukemia blasts but not on hematopoietic stem cells.

[Nature Reviews Immunology] Scientists highlight emerging correlates of response to adoptive cell transfer and novel strategies that integrate tumor immunology, cancer genomics, computational biology, and T cell engineering for the development of next-generation cellular immunotherapies.

[Blood] Investigators tested a broad array of strategies to enhance CD4CAR T-cell efficacy, including CRISPR-Cas9-mediated gene editing of immune checkpoint and HIV-associated genes, single and pooled competitive infusions of engineered CAR T cells, distinct CAR constructs incorporating either CD28 or 4-1BB costimulatory domains, and exogenous antigen boosting.

[Cancer Immunology Research] Researchers evaluated the immunogenicity of Forkhead box protein M1 (FOXM1) and investigated the feasibility of targeting this transcription factor using T-cell receptor (TCR) engineering.

[UMGCCC] The University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) is the first in the Maryland, Delaware, Virginia, and Washington D.C. region to offer a cell therapy treatment for patients with synovial sarcoma.

[International Immunopharmacology] Scientists engineered a CCL19-armed oncolytic adenovirus to enhance the recruitment of CAR-T cells to tumor sites. In vitro, activated CAR-T cells exhibited elevated CCR7 expression, which began to decline after day nine under continuous culture conditions.

[OriCell Therapeutics ] OriCell Therapeutics Holdings Limited announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration to proceed into a confirmatory Phase II clinical trial in patients with GPC3-positive advanced hepatocellular carcinoma.

[Science Advances] Researchers showed that engaging the CAR T cell endogenous T cell receptor (TCR) using an oncolytic virus enhances CAR T cell functionality, durability, and therapy. Upon combination therapy of solid tumors with CAR T cells and vesicular stomatitis virus, a subpopulation of antiviral, TCR-primed CAR T cells is generated with enhanced effector functions when compared to non–TCR-primed CAR T cells.

[Experimental & Molecular Medicine] Single-cell RNA-sequencing and multiplex immunohistochemistry analyses demonstrated upregulated expression of inducible T cell co-stimulator ligand (ICOSLG) and RUNX1 in psoriatic keratinocytes.